Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-06-2013 | Retinal Disorders

Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa

Authors: Mayer Srour, Giuseppe Querques, Nicolas Leveziel, Jennyfer Zerbib, Julien Tilleul, Elise Boulanger-Scemama, Eric H. Souied

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2013

Abstract

Background

To evaluate the anatomical and functional outcomes of intravitreal dexamethasone implant in patients with macular edema (ME) secondary to retinitis pigmentosa (RP).

Methods

Three patients (four eyes), aged 24 to 46 years, presented with refractory ME secondary to RP. Intravitreal dexamethasone implant (Ozurdex) was administered to treat ME. The anatomical (central macular thickness [CMT]) and functional (best-corrected visual acuity [BCVA]) outcomes as well as adverse events were recorded.

Results

All patients completed 6 months follow-up. After intravitreal Ozurdex all patients showed regression of ME. At baseline, mean CMT was 443 ± 185 μm (range 213–619 μm); ME improved to 234 ± 68 μm (range 142–307 μm) at 1 month, to 332 ± 177 μm (range 139–513 μm) at 3 msonth, and to 305 ± 124 μm (range 144–447 μm) at 6 months. Recurrent ME was recorded in 2 patients (both patients at 3 months from intravitreal dexamethasone implant). Retreatment with intravitreal Ozurdex was performed in two patients. Mean BCVA improved form 20/160 (range 20/50–20/200) (baseline) to 20/100 (range 20/40–20/125) at 1 month, to ∼20/125 (range 20/100–20/200) at 3 months, and to ∼ 20/125 (range 20/100–20/160) at 6 months. No serious ocular and systemic adverse events were observed during the study period.

Conclusions

Intravitreal dexamethasone implant provides anatomic and functional improvements and may represent a valuable treatment option for patients with ME secondary to RP.

Newsome DA, Blacharski PA (1987) Grid photocoagulation for macular oedema in patients with retinitis pigmentosa. Am J Ophthalmol 103:161–166PubMed

García-Arumí J, Martinez V, Sararols L, Corcostegui B (2003) Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. Ophthalmology 110:1164–1169PubMedCrossRef

Cox SN, Hay E, Bird AC (1988) Treatment of chronic macular oedema with acetazola- mide. Arch Ophthalmol 106:1190–1195PubMedCrossRef

Saraiva VS, Sallum JMF, Farah ME (2003) Treatment of cystoid macular oedema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 34:398–400PubMed

Scorolli L, Morara M, Meduri A, Reggiani LB, Ferreri G, Scalinci SZ, Meduri RA (2007) Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 125:759–764PubMedCrossRef

Bressler NM, Schachat AP (2010) Management of macular edema from retinal vein occlusions you can never have too many choices. Ophthalmology 117:1061–1063PubMedCrossRef

Goldfien A (1995) Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG (ed) Basic and Clinical Pharmacology, 6th edn. Prentice Hall International, London, pp 592–607

Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125:309–317PubMedCrossRef

Haller J, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146PubMedCrossRef

10.

Heckenlively JR, Jordan BL, Aptsiauri N (1999) Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 127:565–573PubMedCrossRef

11.

Giusti C, Forte R, Vingolo EM (2002) Deflazacort treatment of cystoid macular edema in patients affected by Retinitis Pigmentosa: a pilot study. Eur Rev Med Pharmacol Sci 6:1–8PubMed

12.

Ozdemir H, Karacorlu M, Karacorlu S (2005) Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 83:248–251PubMedCrossRef

13.

SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol 127:1115–1128CrossRef

Title: Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa
Authors: Mayer Srour
Giuseppe Querques
Nicolas Leveziel
Jennyfer Zerbib
Julien Tilleul
Elise Boulanger-Scemama
Eric H. Souied
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2013
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-012-2249-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2013

Emotional wellbeing of blind patients in a pilot trial with subretinal implants

Relationship of change in central corneal thickness to visual field progression in eyes with glaucoma

Dulbecco’s Modified Eagle Medium is neuroprotective when compared to standard vitrectomy irrigation solution

Iatrogenic retinal breaks in 20-G versus 23-G pars plana vitrectomy

Outer retinal tubulations in chronic central serous chorioretinopathy

Retinal neurovascular coupling in patients with glaucoma and ocular hypertension and its association with the level of glaucomatous damage